Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This will be a controlled, randomized, double-blind and double-dummy study on the treatment
augmentation strategy for obsessive compulsive disorder patients non-respondent to first line
pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum
dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the
association of fluoxetine with clomipramine.
Phase:
Phase 4
Details
Lead Sponsor:
University of Sao Paulo
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico Fundação de Amparo à Pesquisa do Estado de São Paulo Novartis